Anson Hsieh, MD
Internal Medicine · Bowling Green, KYNPI 1316940596
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 881 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 881 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- AstraZeneca$1K
- GSK$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Novartis$953
- plus $7K from 45 others
What the payments were for
- Food & beverage$14,54098%
- Education$2222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,762 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 478 | $322,117 |
| EliquisApixaban | 318 | $174,150 |
| OzempicSemaglutide | 157 | $168,954 |
| OtezlaApremilast | 30 | $141,338 |
| LinzessLinaclotide | 207 | $116,345 |
| JanuviaSitagliptin Phosphate | 169 | $112,983 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $80,138 |
| FarxigaDapagliflozin Propanediol | 97 | $73,288 |
| MounjaroTirzepatide | 67 | $69,348 |
| XareltoRivaroxaban | 103 | $60,338 |
| OxycontinOxycodone Hcl | 44 | $56,507 |
| TrulicityDulaglutide | 29 | $44,339 |
| Dupixent PenDupilumab | 11 | $44,218 |
| EntrestoSacubitril/Valsartan | 77 | $37,973 |
| VascepaIcosapent Ethyl | 84 | $34,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $379 | $383,332562 claims |
| PfizerEliquis | $641 | $174,150318 claims |
| AmgenOtezla, Prolia | $1,140 | $170,92947 claims |
| Novo NordiskOzempic | $785 | $168,954157 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $1,921 | $146,728234 claims |
| MerckJanuvia, Janumet | $343 | $122,000182 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,134 | $115,686190 claims |
| Lilly USA, LLCMounjaro, Trulicity | $670 | $113,68896 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,135 | $108,919155 claims |
| Johnson & JohnsonXarelto, Invokana | $334 | $80,289127 claims |
| NovartisEntresto | $953 | $37,97377 claims |
| Astellas Pharma US IncMyrbetriq | $379 | $26,59540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Bowling Green
- Hope HavenerBowling Green$17K
- Sherryl ReedBowling Green$15K
- Fares KhaterWhitesburg$412K
- Bernard BuchananOwensboro$185K
- David ManninoLexington$168K
- John PeppinCynthiana$108K
- Sanjay KaulBrownsville$69K
- John JonesHazard$63K
- Robert SasserLouisville$62K
- Justin LandeDanville$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.